Final-Program-ATS-2023-AP.vp

290

TUESDAY • MAY 23

3:01 E-cigarette Use and Early Transcriptomic Alterations in Human Lung Tissue C. Pascoe, PhD, Winnipeg, MB 3:16 Q&A C. Pascoe, PhD, Winnipeg, MB 3:21 Vaping Old and New and how it Alters Your Respiratory Immune Responses I. Jaspers, PhD, Chapel Hill, NC 3:37 Q&A I. Jaspers, PhD, Chapel Hill, NC 3:42 Exhaling - Closing Remarks, What's Next? M. Perez, MD, Farmington, CT

CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

C91

THE E-CIGARETTE AND VAPING PRODUCT EPIDEMIC: IT'S IN THE JUICE

2:15 p.m. - 3:45 p.m.

Walter E. Washington Convention Center Room 143 A-C

Target Audience Clinical, translational and basic science researchers; those involved with policy development; providers of lung health Objectives At the conclusion of this session, the participant will be able to: • learn new findings about the biological and physiological impacts of e-cigarette and vaping use on the lung. • improve understanding of the epidemiology, pathogenesis and clinical management of E-cigarette or vaping product use-associated lung injury (EVALI) • learn about existing and needed effective policies for the regulation of e-cigarette and vaping product availability. This session features speakers who will summarize up to date knowledge and future direction for research related to biological, physiological and social impacts of e-cigarette use, with particular focus on new users. Topics will include an overview of policy strengths and limitations related to regulation of e-cigarette and e-cigarette juice availability. Specific insight on molecular and cellular responses in the lung will be featured, including tissue remodeling, immunity and inflammation. A recent ATS workshop summary on EVALI will be featured, and the evolution of e-cigarette devices in the last decade will be discussed. Chairing: A. Noel, PhD, Baton Rouge, LA M. Perez, MD, Farmington, CT 2:15 Inhaling- Vaping Updates from Animal and Human Studies A. Noel, PhD, Baton Rouge, LA 2:19 Results from the ATS EVALI Workshop Report - Critical Needs to Prevent Future Outbreaks of Vaping Induced Illness M. Rebuli, PhD, Chapel Hill, NC

CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

C92

ATS PRESIDENT'S SYMPOSIUM: EARLY LIFE DETERMINANTS (ANTECEDENTS) OF ADULT LUNG DISEASE

2:15 p.m. - 3:45 p.m.

Walter E. Washington Convention Center Room 153 A-B (Street Level)

Objectives At the conclusion of this session, the participant will be able to: • review recent advances in our understanding of how premature birth affects lung development and predisposes the individual to childhood and adult diseases such as asthma, COPD, and pulmonary hypertension • understand how early life exposures to airborne pollutants, allergens, cigarette smoke, and particulate matter from wild fires affects lung development and predisposes the individual to childhood and adult diseases such as asthma and COPD • highlight the areas of research needed to reduce the impact of early life exposures disease on respiratory health in children and adults This symposium will focus on the early life determinants of lung health throughout the lifespan beginning in utero and extending into childhood and adulthood. The lungs of babies born premature are not fully developed and are more susceptible to respiratory infections or inhaled toxicants. Diseases that manifest clinically in utero and in childhood such as cystic fibrosis and sickle cell anemia result in lung injury and these individuals are more susceptible to and have less reserve to withstand additional insults such as respiratory infections or exposure to pollutants such as automobile exhaust, ozone, aeroallergens, and airborne particulate matter from wildfires. In adulthood, these early life factors predispose to asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pulmonary hypertension. The mechanisms of lung injury and physiological consequences of these early life

2:35

Q&A M. Rebuli, PhD, Chapel Hill, NC

2:40

E-cigarettes: Mice, Humans, and Policy, Oh My! L. Crotty-Alexander, PhD, La Jolla, CA

2:56

Q&A L. Crotty-Alexander, PhD, La Jolla, CA

ATS 2023 • Washington, DC